Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Over the past decade, targeted radionuclide therapy has progressed substantially, especially for the treatment of neuroendocrine tumours. The frequent overexpression of prostate-specific membrane antigen (PSMA) in prostate cancers opened the way for the development of tracers for diagnostic purposes and for therapeutic applications, thereby offering a more precise and personalised approach for the treatment of castration-resistant tumours. 1 Baum RP Kulkarni HR Schuchardt C et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016; 57: 1006-1013 Crossref PubMed Google Scholar [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialThe addition of [177Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival providing evidence of enhanced anticancer activity in patients with metastatic castration-resistant prostate cancer with risk factors for early progression on enzalutamide and warrants further evaluation of the combination more broadly in metastatic prostate cancer. Full-Text PDF